Levels of p53 in Epstein-Barr virus-infected cells determine cell fate: Apoptosis, cell cycle arrest at the G1/S boundary without apoptosis, cell cycle arrest at the G2/M boundary without apoptosis, or unrestricted proliferation

Virology

Volumn 251, Issue 2, 1998, Pages 217-226

  Chen, Weiping ^a   Huang, Shuang ^a   Cooper, Neil R ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; PROTEIN P21; PROTEIN P53;

APOPTOSIS; ARTICLE; BURKITT LYMPHOMA; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL LEVEL; CELL PROLIFERATION; DOSE RESPONSE; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; LYMPHOBLASTOID CELL LINE; MITOSIS INHIBITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TEMPERATURE SENSITIVE MUTANT; VIRUS CELL INTERACTION;

EID: 0032567121     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.1998.9431     Document Type: Article

References (49)

1. Allday M. J., Inman G. J., Crawford D. H., Farrell P. J. DNA damage in human B cells can induce apoptosis, proceeding from G1/S when p53 is transactivation competent and G2/M when it is transactivation defective. EMBO J. 14:1995a;4994-5005.
2. Allday M. J., Sinclair A., Parker G., Crawford D. H., Farrell P. J. Epstein-Barr virus efficiently immortalizes human B cells without neutralizing the function of p53. EMBO J. 14:1995b;1382-1391.
3. Aloni-Grinstein R., Zan-Bar I., Alboum I., Goldfinger N., Rotter V. Wild type p53 functions as a control protein in the differentiation pathway of the B-cell lineage. Oncogene. 8:1993;3297-3305.
4. Baker S. J., Markowitz S., Fearon E. R., Willson J. K. V., Vogelstein B. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science. 249:1990;912-915.
5. Calender A., Billaud M., Aubry J.-P., Banchereau J., Vuillaume M., Lenoir G. M. Epstein-Barr virus (EBV) induces expression of B-cell activation markers onin vitro. Proc. Natl. Acad. Sci. USA. 84:1987;8060-8064.
6. Chen W., Cooper N. R. Epstein-Barr virus nuclear antigen 2 and latent membrane protein independently transactivate p53 through induction of NF-κB activity. J. Virol. 70:1996;4849-4853.
7. Chen W., Lee Y., Wang H., Yu G.-G., Jiao W., Zhou W., Zeng Y. Suppression of human nasopharyngeal carcinoma cell growth in nude mice by the wild-type p53 gene. J. Cancer Res. Clin. Oncol. 119:1992;46-48.
8. Clarke A. R., Purdie C. A., Harrison D. J., Morris R. G., Bird C. C., Hooper M. L., Wyllie A. H. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature. 362:1993;849-852.
9. Donehower L. A., Harvey M., Slagle B. L., McArthur M. J., Montgomery C. A. Jr., Butel J. S., Bradley A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 356:1992;215-221.
10. El-Deiry W. S., Tokino T., Velculescu V. E., Levy D. B., Parsons R., Trent J. M., Lin D., Mercer W. E., Kinzler K. W., Vogelstein B. WAF1, Cell. 75:1993;817-825.
11. Farrell P. J., Allan G. J., Shanahan F., Vousden K. H., Crook T. p53 is frequently mutated in Burkitt's lymphoma cell lines. EMBO J. 10:1991;2879-2887.
12. Fries K. L., Miller W. E., Raab-Traub N. Epstein-Barr virus latent membrane protein 1 blocks p53-mediated apoptosis through the induction of the A20 gene. J.Virol. 70:1996;8653-8659.
13. Ginsberg D., Michael-Michalovitz D., Oren M. Induction of growth arrest by a temperature-sensitive p53 mutant is correlated with increased nuclear localization and decreased stability of the protein. Mol. Cell. Biol. 11:1991;582-585.
14. Greenblatt M. S., Bennett W. P., Hollstein M., Harris C. C. Mutations in thep53. Cancer Res. 54:1994;4855-4878.
15. Harper J. W., Adami G. R., Wei N., Keyomarsi K., Elledge S. J. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell. 75:1993;805-816.
16. Henderson S., Rowe M., Gregory C., Croom-Carter D., Wang F., Longnecker R., Kieff E., Rickinson A. Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell. 65:1991;1107-1115.
17. Hermeking H., Lengauer C., Polyak K., He T.-C., Zhang L., Thiagalingam S., Kinzler K. W., Vogelstein B. 14-3-3ς is a p53-regulated inhibitor of G2/M progression. Mol. Cell. 1:1998;3-11.
18. Hollstein M., Rice K., Greenblatt M. S., Soussi T., Fuchs R., Sorlie T., Hovig E., Smith-Sorensen B., Montesano R., Harris C. C. Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res. 22:1994;3551-3555.
19. Hollstein M., Sidransky D., Vogelstein B., Harris C. p53 mutations in human cancers. Science. 253:1991;49-53.
20. Huang S., Stupack D. G., Mathias P., Wang Y., Nemerow G. Growth arrest of Epstein-Barr virus immortalized B lymphocytes by adenovirus-delivered ribozymes. Proc. Natl. Acad. Sci. USA. 94:1997;8156-8161.
21. Hunter T. Braking the cycle. Cell. 75:1993;839-841.
22. Kastan M. B., Onyekwere O., Sidransky D., Vogelstein B., Craig R. W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51:1991;6304-6311.
23. Laherty C. D., Hu H. M., Opipari A. W., Wang F., Dixit V. M. The Epstein-Barr virus LMP1 gene product induces A20 zinc finger protein expression by activating nuclear factor κB. J. Biol. Chem. 267:1992;24157-24160.
24. Lane D. P. p53, guardian of the genome. Nature. 358:1992;15-16.
25. Lavigueur A., Maltby V., Mock D., Rossant J., Pawson T., Bernstein A. High incidence of lung, bone, and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene. Mol. Cell. Biol. 9:1989;3982-3991.
26. Lechner M. S., Mack D. H., Finicle A. B., Crook T., Vousden K., Laimins L. Human papillomavirus E6 proteins bind p53in vivo. EMBO J. 11:1992;3045-3052.
27. Levine A. J. p53, the cellular gatekeeper for growth and division. Cell. 88:1997;323-331.
28. Lowe S. W., Schmitt E. M., Smith S. W., Osborne B. A., Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature. 362:1993;847-849.
29. Ludlow J. W. Interactions between SV40 large-tumor antigen and the growth suppressor proteins pRB and p53. FASEB J. 7:1993;866-871.
30. Mann K. P., Staunton D., Thorley-Lawson D. A. Epstein-Barr virus-encoded protein found in plasma membranes of transformed cells. J.Virol. 55:1985;710-720.
31. Marx J. Howp53. Science. 262:1994;1644-1645.
32. Milner J., Medcalf E. A. Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation. Cell. 65:1991;765-774.
33. Nemerow G. R., Cooper N. R. Isolation of Epstein-Barr virus and studies of its neutralization by human IgG and complement. J. Immunol. 127:1981;272-278.
34. Okan I., Wang Y., Chen F., Hu L.-F., Imreh S., Klein G., Wiman K. G. The EBV-encoded LMP1 protein inhibits p53-triggered apoptosis but not growth arrest. Oncogene. 11:1995;1027-1031.
35. Oren M. p53: The ultimate tumor suppressor gene. FASEB J. 6:1992;3169-3176.
36. Ramqvist T., Magnusson K. P., Wang Y., Szekely L., Klein G., Wiman K. G. Wild-type p53 induces apoptosis in a Burkitt lymphoma (BL) line that carries mutant p53. Oncogene. 8:1993;1495-1500.
37. Sarnow P., Ho Y. S., Williams J., Levine A. J. Adenovirus E1b-58kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54kd cellular protein in transformed cells. Cell. 28:1982;387-394.
38. Shaulsky G., Goldfinger N., Peled A., Rotter V. Proc. Natl. Acad. Sci. USA. 88:1991;8982-8986.
39. Sorenson C. M., Barry M. A., Eastman A. Analysis of events associated with cell cycle arrest at G2 phase and cell death induced by cisplatin. J. Natl. Cancer Inst. 82:1990;749-755.
40. Stewart N., Hicks G. G., Paraskevas F., Mowat M. Evidence for a second cell cycle block at G2/M by p53. Oncogene. 10:1995;109-115.
41. Szekely L., Pokrovskaja K., Jiang W.-Q., Selivanova G., Löwbeer M., Ringertz N., Wiman K. G., Klein G. Resting B-cells, EBV-infected B-blasts and established lymphoblastoid cell lines differ in their Rb, p53 and EBNA-5 expression patterns. Oncogene. 10:1995;1869-1874.
42. Ullrich S. J., Mercer W. E., Appella E. Human wild-type p53 adopts a unique conformational and phosphorylation statein vivo. Oncogene. 7:1992;1635-1643.
43. Wang D., Liebowitz D., Kieff E. An Epstein-Barr virus membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell. 43:1985;831-840.
44. Wang F., Tsang S.-F., Kurilla M. G., Cohen J. I., Kieff E. Epstein-Barr virus nuclear antigen 2 transactivates latent membrane protein LMP1. J. Virol. 64:1990;3407-3416.
45. Williams B. O., Remington L., Albert D. M., Mukai S., Bronson R. T., Jacks T. Cooperative tumorigenic effects of germline mutations in Rb and p53. Nature Genet. 7:1994;480-484.
46. WAF1/CIP1. J. Exp. Med. 187:1998;1671-1679.
47. Yonisch-Rouach E., Resnitzky D., Lotem J., Sachs L., Kimchi A., Oren M. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature. 352:1991;345-347.
48. Young L., Alfieri C., Hennessy K., Evans H., O'Hara C., Anderson K. C., Ritz J., Shapiro R. S., Rickinson A., Kieff E., Cohen J. I. Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. N. Engl. J. Med. 321:1989;1080-1085.
49. Zhang W., Guo X.-Y., Liu W.-B., Shay J. W., Deisseroth A. B. A temperature-sensitive mutant of human p53. EMBO J. 13:1994;2535-2544.